Antibe Therapeutics increases previously announced non-brokered private placement to up to $5,000,000

Antibe Therapeutics Inc. ("Antibe" or the "Corporation") (TSXV:ATE) is pleased to announce, based on increased inbound demand, that the previously announced non-brokered private placement (the "Offering") has been increased to up to $5,000,000 on the same terms and conditions as announced in Antibe's press release dated March 21, 2014.

The Offering is expected to close in one or more closings, with the first closing expected on March 31, 2014, subject to TSXV approval, and to the satisfaction of customary closing conditions.

Net proceeds from the Offering will be used for product development and for general corporate purposes.

The Offering will be made as a non-brokered private placement, exempt from prospectus and registration requirements of applicable securities laws and the securities to be issued will be subject to a four-month hold period. Finder's fees will be payable in the amount of 10% of the gross proceeds in cash and 10% Common Share purchase warrants ("Finder's Warrants"), each of which will entitle the holder to purchase a Common Share at a price of $0.60 per share for a term of two (2) years following the date of issuance.